Samsung Biologics, a global CDMO providing end-to-end contract development and manufacturing services, unveiled plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for many COVID-19 vaccines due to its characteristics of safety and fast scalability in manufacturing.   As part of the company’s long-term strategy to become a fully...